Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | GRK2 | P25098 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RGS12 | O14924 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21684626 | 0.86 | MAP4K1 (0.35) | MAP4K1XDHTLR7 | |
| SCHEMBL21703438 | 0.86 | MAP4K1 (0.41) | MAP4K1MAPK14TLR7 | |
| SCHEMBL21703332 | 0.84 | MAP4K1 (0.55) | MAP4K1SMN1; SMN2MAPK14MEN1ALDH1A1 | |
| SCHEMBL21703080 | 0.82 | MAP4K1 (0.42) | MAP4K1 | |
| SCHEMBL21703079 | 0.80 | MAP4K1 (0.42) | MAP4K1 | |
| SCHEMBL21685522 | 0.76 | MAP4K1 (0.45) | MAP4K1MAPK14 | |
| SCHEMBL25948627 | 0.75 | MAP4K1 (0.61) | MAP4K1 | |
| SCHEMBL21685192 | 0.73 | ALDH1A1 (0.42) | MAP4K1SMN1; SMN2ALDH1A1HTTXDH | |
| SCHEMBL25948635 | 0.73 | MAP4K1 (0.46) | MAP4K1MAPK14 | |
| SCHEMBL21703330 | 0.72 | MAP4K1 (0.43) | MAP4K1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020033784-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| US-20160213763-A1 | NOVEL GLYCAN CONJUGATES AND METHODS OF USE THEREOF | ACADEMIA SINICA (TW) | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | MAP4K1 2520/4885SMN1; SMN2 2176/4885MAPK14 3990/4885 |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | MAP4K1 2520/4885SMN1; SMN2 2176/4885MAPK14 3990/4885 |
| US-20160213763-A1 | NOVEL GLYCAN CONJUGATES AND METHODS OF USE THEREOF | B3GAT3, ST6GAL1, STT3A | MAP4K1 1943/4885SMN1; SMN2 3550/4885MAPK14 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.